CAMBREX CORPORATION (NYSE:CBM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
On April 27, 2017, the Company held its annual meeting of
stockholders to notice duly given. At the meeting, the
stockholders voted on the following five proposals and cast their
votes as described below. For more information about the
proposals set forth below, please see the Companys definitive
proxy statement filed with the Securities and Exchange Commission
on March 21, 2017.
1. Proposal 1 Election of Directors. All of the nominees
for director were elected for a term expiring at the next annual
meeting of stockholders and until their successors are duly
elected and qualified by the votes set forth in the table below:
|
|
For |
Against |
Abstain |
Broker Non-Votes |
|
Rosina B. Dixon |
28,598,156 |
438,027 |
9,266 |
1,388,231 |
|
Claes Glassell |
28,726,710 |
309,753 |
8,986 |
1,388,231 |
|
Louis J. Grabowsky |
28,761,600 |
274,563 |
9,286 |
1,388,231 |
|
Bernhard Hampl |
28,758,426 |
277,734 |
9,289 |
1,388,231 |
|
Kathryn Rudie Harrigan |
28,622,632 |
413,551 |
9,266 |
1,388,231 |
|
Ilan Kaufthal |
28,550,726 |
485,236 |
9,487 |
1,388,231 |
|
Steven M. Klosk |
28,734,429 |
302,272 |
8,748 |
1,388,231 |
|
Peter G. Tombros |
28,545,487 |
490,317 |
9,645 |
1,388,231 |
|
Shlomo Yanai |
28,594,079 |
442,084 |
9,286 |
1,388,231 |
2. Proposal 2 Say on Pay. The Companys stockholders
approved, on an advisory basis, the compensation of the Companys
named executive officers as disclosed in the definitive proxy
statement, as set forth below:
|
For |
Against |
Abstain |
Broker Non-Votes |
|
28,449,340 |
566,409 |
29,700 |
1,388,231 |
. Proposal 3 Frequency of Say on Pay Vote. The Companys
stockholders voted, on an advisory basis, that the frequency of
named executive officer compensation advisory votes should be
every year, as set forth below:
|
1 year |
2 years |
3 years |
Abstain |
Broker Non-Votes |
|
24,544,467 |
83,239 |
4,400,034 |
17,709 |
1,388,231 |
Based on these results, and consistent with the recommendation of
the Companys board of directors (the Board), the Board has
determined that the Company will hold an advisory vote on named
executive officer compensation every year.
4. Proposal 4 Approval of Amended and Restated Executive Cash
Incentive Plan. The Companys stockholders approved the
Companys Amended and Restated Executive Cash Incentive Plan, as
disclosed in the definitive proxy statement, as set forth below:
|
For |
Against |
Abstain |
Broker Non-Votes |
|
28,563,335 |
452,487 |
29,627 |
1,388,231 |
5. Proposal 5 Ratification of Independent Registered Public
Accountants. The Companys stockholders ratified the
appointment of BDO USA, LLP as the Companys independent
registered public accountants for the fiscal year ending December
31, 2017, by the votes set forth in the table below:
|
For |
Against |
Abstain |
|
30,124,454 |
301,770 |
7,456 |
The proposal to ratify the appointment of BDO USA, LLP was a
routine matter and, therefore, there were no broker non-votes
relating to that matter.
About CAMBREX CORPORATION (NYSE:CBM)
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities. The Company’s manufacturing facilities are located in the Europe and the United States. The Company’s business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and other fine chemicals. The Company’s products and services are sold around the world under trademarks that are owned by the Company. This includes Profarmaco, which is registered around the world as a word and design mark. Its products are sold through a combination of direct sales and independent agents. CAMBREX CORPORATION (NYSE:CBM) Recent Trading Information
CAMBREX CORPORATION (NYSE:CBM) closed its last trading session down -1.20 at 58.15 with 344,787 shares trading hands.